ABSTRACT
Cellular senescence and DNA methylation are primary aging mechanisms emerging as a potential means of monitoring human aging and evaluating interventions thought to either accelerate or slow an individual’s aging trajectory. However, it is largely unknown whether cellular senescence and signatures of methylation of the specific CpG islands that comprise various epigenetic clocks correlate in humans. We have measured the cellular senescence biomarker, p16 and the five most used epigenetic aging clocks in 251 patients with breast cancer, 49 age-matched non-cancer controls, and 48 patients undergoing cytotoxic chemotherapy treatment. Chemotherapy, a known clinically-relevant inducer of aging, increased expression of p16 but not levels of the most common epigenetic clocks (DNAm-Horvath, PhenoAge, GrimAge, mPoA), with the exception of DNAm-Hannum. Chemotherapy-induced changes in p16 were associated with increased levels of a subset of SASPs, PARC, TNFRII, ICAM1, and TNFa. Cross-sectionally, there was weak to no correlation between p16 expression and epigenetic clocks in cancer patients or non-cancer controls. GrimAge and PhenoAge were the most correlated with p16 (r<0.3), with no correlation between p16 and the pace of aging epigenetic clock. Together, these data show that there is a general discordance between measures of cellular senescence and epigenetic clocks with the senescence marker p16 but not epigenetic clocks of aging responding to a clinically relevant inducer of human aging, cytotoxic chemotherapy.
Competing Interest Statement
NM is a co-founder of Sapere Bio. NM, SLS, and AK are equity holders in the company and inventors on intellectual property applications. Mayo Clinic and NKL have relevant technology licensed to a commercial entity. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and is being conducted in compliance with Mayo Clinic Conflict of Interest policies. Other authors report no conflict of interest
Funding Statement
This work was supported by grants from Breast Cancer Research Foundation, New York, NY, the Kay Yow Cancer Fund, Cary, NC, the UNC Lineberger Comprehensive Cancer Center/University Cancer Research Fund and NIH/NCI R01 CA203023 to HM. NKL is supported by the NIH/NIA, including R01 AG55529 and R56 AG60907, and the Glenn Foundation for Medical Research. The funding sources had no involvement in the study design or in the collection, analysis and interpretation of data. The funding sources also had no involvement in the writing of this report or in the decision to submit the report for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Two Trials used in this study, NCT#02328313 and 02167932 that included the University of North Carolina Cohort were approved but the Institutional Review Board of the University of North Carolina, Chapel Hill, NC The City of Hope Cohort included patients from NCT# 0142094 and was approved by the Institutional Review Boards of: City of Hope Medical Center, Duarte, California Yale University New Haven, Connecticut University of Chicago, Chicago, Illinois, Massachusetts General Hospital, Boston, Massachusetts Dana-Farber Cancer Institute, Boston, Massachusetts Washington University St. Louis, Missouri Roswell Park Cancer Institute, Buffalo, New York Hofstra-North-Long Island Jewish Cancer Institute, New Hyde Park, New York Memorial Sloan-Kettering Cancer Center, New York, New York University of Rochester Medical Center, Rochester, New York. University of North Carolina, Chapel Hill, North Carolina Wake Forest University, Winston-Salem, North Carolina Case Western Reserve University, Cleveland, Ohio Thomas Jefferson University, Philadelphia, Pennsylvania Fox Chase Cancer Center, Philadelphia, Pennsylvania Rhode Island Hospital, Providence, Rhode Island University of Virginia Health System, Charlottesville, Virginia
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data can be requested from the senior author
